Meyka AI API is live for developers.Start building.
Advertisement
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR) Stock Overview

Explore Kymera Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

KYMR●NASDAQ
HealthcareBiotechnology
$99.87
$1.62(1.65%)
U.S. Market opens in 7h 41m
Advertisement

Kymera Therapeutics, Inc. (KYMR)

Meyka AI Score

Z

Key Financials

Market Cap8.2B
P/E Ratio-27.78
EPS (TTM)$-3.53
ROE-0.25%
Fundamental Analysis

AI Price Forecasts

1 Month$97.61
3 Months$115.57
1 Year Target$95.11

KYMR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Kymera Therapeutics, Inc. (KYMR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 74.75, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $95.11.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -27.78 and a market capitalization of 8.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.65%
5-Day Change
7.57%
1-Month Change
26.59%
3-Month Change
34.20%
6-Month Change
20.14%
Year-to-Date (YTD) Change
28.35%
1-Year Change
111.86%
3-Year Change
342.10%
5-Year Change
125.49%
All-Time (Max) Change
200.27%

Contact Information

https://www.kymeratx.com
857 285 5300
200 Arsenal Yards Boulevard, Watertown, MA, 02472

Company Facts

2,080 Employees
IPO DateAug 21, 2020
CountryUS
Actively Trading

Frequently Asked Questions